Goya CEO slams Biden-Harris admin as ‘complicit’ in child and drug trafficking at border

 Goya Foods CEO Robert Unanue accused the Harris-Biden administration of being “complicit” in child trafficking and human trafficking by failing to control the southern border.

Unanue leveled the claim after criticizing Vice President Kamala Harris’ pivot to focus on “price controls” for groceries and other goods.

“How about the United States — instead of being the complicit middlemen in child trafficking, human trafficking and drugs — why don’t they put a lid on that and control our borders,” Unananue said Sunday during an interview on WABC’s “The Cats Roundtable.”

The business leader said he met with Salvadoran President Nayib Bukele and applauded his crackdown on gang members that locked up thousands of thugs who terrorized the country’s citizens.

But, he said, scores of El Salvador’s notorious MS-13 gang members crossed the border into the U.S. and are now terrorizing residents here, including other Salvadoran migrants.

“The horses are already out of the barn. And those gang members and those gang members from Venezuela and other countries are in our country ravaging suburban neighborhoods, scaring people,” Inanue, the CEO of the New Jersey-based Latino food giant Goya since 2004.

He said some Salvadorans who fled to the U.S. now want to move back “because of safety” concerns and being harassed by MS-13 thugs.

“Of course, El Salvador is not an economic paradise,” the food magnate said.

Unanue is a vocal backer of former President Trump, the Republican nominee, and spoke at the Republican National Convention in July. 

He provoked a boycott of Goya Foods after he said, in remarks at the White House in 2020, “We’re all truly blessed to have a leader like President Trump.”

The board of Goya Foods censured Unanue in 2021 after he questioned the legitimacy of the 2020 presidential election and barred him from making public statements without the board’s say so.

But Unanue is now releasing a book titled, “Blessed, Donald J. Trump and the Spiritual War: How the Battle for the Soul of this Country Began With One Word.” 

3

Unanue leveled the claim after criticizing Vice President Kamala Harris’ pivot to focus on “price controls” for groceries and other goods.Josh Morgan/USA TODAY / USA TODAY NETWORK
To back up the argument in his book, he noted that Trump survived an assassination attempt at a Pennsylvania rally on July 13, how “he turned his head at the right moment.”

“I think God had his hand on Donald Trump and this nation,” he said, while “this administration [Harris-Trump] has destroyed it.”

He also ripped the Harris-Biden administration for stopping the Keystone pipeline to expand oil delivery from Canada to the U.S. and called the Green New Deal “crazy.”

The Harris campaign had no immediate comment.

https://nypost.com/2024/09/01/us-news/goya-ceo-slams-biden-harris-admin-as-complicit-in-child-and-drug-trafficking-at-border/

15 ‘rules for radicals’ to get far-left Kamala Harris elected

 How do accomplished radicals elect a mediocre far-left presidential candidate?

The task might at first seem impossible.

Kamala Harris is currently a radical incumbent vice president.

For more than three years, she was second in command to an unprecedentedly unliked Democratic president, his failed policies and his unpopular record.

Harris herself had compiled a hard-left trail over her own entire career while loudly boasting indiscreetly to leftist audiences of being proudly “woke” and “radical.”

Most challenging for a Harris candidacy makeover was the long, entrenched Democratic Party’s reluctance to remove a debilitated President Biden from the Democratic ticket.

Why?

Because Harris was deemed such a liability that she had become a Spiro Agnew-like insurance policy for a failing Biden.

Until just recently, Democrats had considered an unpopular and enfeebled Biden nonetheless far preferable to an incoherent, lightweight and widely ridiculed potential replacement Vice President Harris.

After all, she had never before entered a presidential primary.

She never won a single delegate by voting.

She failed miserably as a candidate in 2020.

And she co-owns the unpopular record of an even more unpopular president.

The complete Harris makeover requires 15 radical rules followed to the letter:

1. Remake Harris as an entirely fresh, happy face. She’s about joy and vibe — which beats position papers and policy statements. Banish all thoughts that she is an incumbent vice president and co-owns the last four years of the Biden administration.
2. Ignore/deny that Harris as vice president could have long ago enacted her new makeover proposal — or could do so right now in the remaining five months of her administration’s tenure. She was the last person out of the room when Biden made those awful decisions.
3. For the next 70 days, reinvent Harris as a moderate. Xerox much of Donald Trump’s current, more popular agenda. Have Harris claim it as her own. Reboot her as a border hawk, a China hawk, a defense hawk, a budget hawk, and a law-and-order hawk.
4. The word-salad Harris must not do a single unscripted media interview, live town hall, extemporaneous chat, ambush hot mic, or lecture without a teleprompter.
5. Harris must not offer any policy proposals such as her harebrained price controls that deviate from her 70-day new centrist image and teleprompted scripts.
6. Do not mention Biden at all. Harris is not to be seen with him in photos or at events. Create a vaguely joyful, but completely imaginary, “Harris record.” Separate it from the miserable Biden-Harris administration. Leak that she was unhappy with Biden.
7. Call Trump a mobster, criminal, insurrectionist and dictator nonstop. Never provide any evidence to support such charges. When challenged, double down and let loose with worse invective.
8. Talk about abortion nonstop. But never dare mention the word. Relabel abortion “reproductive rights.” Falsely reinvent Trump as a radical anti-abortionist who wants a federal ban.
9. Follow the 2020 successful Biden “basement” strategy: Keep out of the public eye, silent on the issues, reliant on 70% of the ballots not being cast on Election Day, and outsourcing the campaign to the fusion media and billionaire class.
10. Harangue about race and gender nonstop. Define the election as a stark binary between a “young” oppressed but dynamic black woman and an old oppressor racist white guy.
11. Reinvent the “journey” and life “story” of Harris — the child of two PhDs — into a hardscrabble, lifelong struggle against poverty, systemic racism, and greedy “billionaires” like Trump. She is always to be from Oakland — never Berkeley.
12. Talk about transparency nonstop. Feign a willingness to have three or four debates. But agree to hold only one — and only on a left-wing network. Promise interviews and town halls endlessly. Enter into discussions about them. But always delay, stonewall, and evade for the next 10 weeks.
13. Meet privately and endlessly with the megarich donor class that helped to remove Biden. Assure Wall Street, Hollywood and Silicon Valley grandees that banter about wealth taxes, taxes on unearned income and higher corporate taxes are mere campaign posturing. Then outraise Trump again 3 to 1.
14. Privately assure leftist activists and Democratic politicos that any backslidings from supporting lifelong left-wing advocacies are temporary and necessary 70-day pretexts. Instead look at what Harris actually does after Nov. 5, not anything she must say before then.
15. Control and modulate the street. Anti-Trump protests are a legitimate “movement” that are “not going to let up. And they should not.” Any violent anti-Trump demonstrator should be bailed out immediately.
16. All anti-Democrat, anti-Harris demonstrations should be deterred.

A large police presence must be proactive with as many arrests as possible, with barriers, and plenty of backup.

Protest leaders should be given private concessions and incentives to tone down their people.

Victor Davis Hanson is a distinguished fellow of the Center for American Greatness.

https://nypost.com/2024/09/02/opinion/these-rules-for-radicals-will-get-far-left-kamala-harris-elected/

Bayer Kerendia works in heart failure, but how might it be used?

 Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is some debate about how the drug may be used in clinical practice.

Kerendia (finerenone) is the first drug in its class to show a benefit in heart failure, achieving a statistically significant improvement in cardiovascular outcomes in heart failure patients with mildly reduced or preserved left ventricular ejection fraction (LVEF) of 40% or greater, according to data presented at the European Society of Cardiology (ESC) congress over the weekend.

Patients with LVEF of 40% or more account for around half of all heart failure patients, but have few available therapies, unlike heart failure with reduced ejection fraction (HFrEF). The life expectancy rate for patients hospitalised with heart failure is worse than many cancers.

Bayer's drug reduced the risk of the composite primary endpoint of cardiovascular death and hospitalisations or urgent visits for heart failure by 16% compared to placebo over a median follow-up of 32 months in the 6,000-patient study, which has also been published in the New England Journal of Medicine.

The result is a key component of Bayer's plan to build Kerendia – which is already approved to treat chronic kidney disease associated with type 2 diabetes – into a major near-term growth driver with a sales target of €3 billion ($3.3 billion). It has a long way to go, with sales of the drug coming in at €200 million in the first half of this year.

The challenge for Bayer will be carving out a role for Kerendia in mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) heart failure alongside SGLT2 inhibitors – AstraZeneca's Farxiga (dapagliflozin) and Eli Lilly/Boehringer Ingelheim's Jardiance (empagliflozin) – which are the only approved therapies for these patients recommended in treatment guidelines.

Novartis' Entresto (sacubitril/valsartan) is also an FDA-approved option for HFmrEF and HFpEF, although, it is recognised most of the drug's benefit comes from patients at the lower end of the LVEF spectrum.

No effect on cardiovascular death

There was discussion at ESC whether Kerendia should be used in place of the SGLT2 inhibitors, or in combination, given that all the benefits of the drug were tied to improvements in heart failure worsening – i.e., hospitalisations – rather than cardiovascular death. An effect on cardiovascular death can be tough to show in a single HFpEF trial, however, as the number of events will be low in an HFpEF population.

It is notable, though, that FINEARTS-HF included patients (around 14%) who were already on SGLT2 drugs, and the efficacy in that group was consistent with that in the overall study population, pointing to a benefit of dual use.

On safety, Kerendia was associated with a higher rate of elevated potassium levels in the blood (hyperkalaemia), but that reflects its mechanism of action and hospitalisation rates were low at 0.5% versus 0.2% for placebo.

"The FINEARTS-HF trial provides the first definite evidence that an MRA is beneficial in HFmrEF/HFpEF," according to Professor Scott Solomon, of Brigham and Women's Hospital in Boston, US, who is principal investigator for FINEARTS-HF and presented the results at ESC.

"We have four pillars of guideline-directed medical therapy in HFrEF, but only SGLT2 inhibitors as a treatment option for HFmrEF/HFpEF," he said. "Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF."

Bayer is running an open-label study – CONFIRMATION-HF – testing Kerendia with Jardiance in patients hospitalised or recently discharged with heart failure, regardless of their LVEF status. It is also testing the drug in the REDEFINE-HF trial as monotherapy in patients with an LVEF of 40% or more, and the FINALITY-HF study as a monotherapy in those with an LVEF below 40%.

The company is preparing to file for approval of the heart failure indication and has said it is hoping for a green light from regulators next year.

https://pharmaphorum.com/news/kerendia-works-heart-failure-how-might-it-be-used

Alnylam hails vutrisiran data, but investors also sceptical

 Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to have disappointed investors.

Shares in the company retreated after the presentation of the results at the European Society of Cardiology (ESC) conference, which confirmed a 28% reduction in the primary endpoint of deaths from any cause and recurrent cardiovascular events after at least 33 months of follow-up.

The total population also included patients also being treated with Pfizer’s blockbuster ATTR-cardiomyopathy drug Vyndamax (tafamidis meglumine) at baseline, and vutrisiran performed even better if it was used on its own, with a 33% reduction in the primary endpoint.

New data reported at ESC included a 36% reduction in deaths and recurrent cardiovascular events at month 42 for the overall cohort and 35% for the monotherapy group, which accounted for two-thirds of patients in the study. There was also a 22% reduction in those taking vutrisiran and Vyndamax together.

Alnylam’s chief medical officer, Pushkal Garg, said the data “suggest[s] that vutrisiran has the potential to become a new standard of care treatment for ATTR-CM, a progressive and ultimately fatal disease with limited treatment options.”

The 8.5% fall in the company’s shares – which still leaves the stock well above its level before the top-line data reveal in June – came despite the gene-silencing drug showing a statistically significant improvement on all of the primary and secondary endpoints in HELIOS-B, along with “strong trends” that adding the drug to Vyndamax boosts efficacy.

Vutrisiran is already approved as Amvuttra to treat polyneuropathy caused by ATTR, but extending its indications to include cardiomyopathy is seen as the key to unlocking sales that analysts at Goldman Sachs have suggested could top $5 billion at peak. It made $425 million in the first six months of the year.

Pfizer’s once-daily oral tafamidis therapies Vyndamax and Vyndaqel grew 39% last year to more than $3.3 billion, coming from sales in both ATTR cardiomyopathy and polyneuropathy. Basic patents are, however, due to expire in the US later this year and in Europe in 2026. Pfizer has been working to extend its patent life, but several generic drugmakers have filed copycat versions for approval.

Adding to tafamidis’ efficacy is seen as crucial for vutrisiran as it means the drug – which is administered by physician-administered subcutaneous injection once every three months – can be used both as a monotherapy and combination therapy option, which could be particularly important once cut-price tafamidis generics become available.

One reason for the fall could be the competitive threat posed by BridgeBio’s acoramidis, which demonstrated a 42% reduction in all-cause mortality and recurrent cardiovascular events in its phase 3 ATTRibute-CM trial and could be approved by the FDA in November. Shares in BridgeBio rose 13% after the ESC presentation.

Another potential rival is AstraZeneca and Ionis’ Wainua (eplontersen) – which is administered by self-injection every three months and is already approved for ATTR polyneuropathy. It is in the CARDIO-TTRansform study in ATTR cardiomyopathy, with results due next year.

HELIOS-B principal Investigator Professor Marianna Fontana, of University College London and the Royal Free Hospital in the UK, who presented the data at ESC, said: “Vutrisiran was highly effective and well tolerated in this contemporary population representative of patients that we see in our clinics, with consistent benefits regardless of background tafamidis therapy.”

She added: “This trial is also important as it is the first to show the benefit of gene silencers in any type of cardiomyopathy.”

https://pharmaphorum.com/news/alnylam-hails-vutrisiran-data-investors-seem-sceptical

'iRhythm wearable heart monitor raises AFib diagnoses by 52%'

 Screening people in primary care with a wearable heart monitor developed by iRhythm was able to increase diagnoses of atrial fibrillation (AFib) by 52%, although it did not result in a reduction in hospitalisations for stroke.

The GUARD-AF study recruited almost 12,000 patients aged 70 or above across the US who wore the Zio XT single-lead electrocardiogram (ECG) device for two weeks. The aim was to see if it was better at spotting AFib than regular care, which could allow earlier treatment with oral anticoagulants to prevent ischaemic stroke – a common complication associated with the heart rhythm disturbance.

Results presented at the European Society of Cardiology (ESC) congress showed that the higher AFib diagnosis rate over an average 15 months of follow-up – 5.0% vs 3.3% with standard care – was accompanied by an increase in anticoagulant therapy (4.2% vs 2.8%), with no increase in hospitalisations for bleeding complications.

The failure to show a reduced rate of hospitalisations for stroke was a disappointment, given that AFib raises the risk five-fold, but likely a result of the trial having to be stopped early due to COVID-19 lockdowns, according to lead investigator Professor Renato Lopes, of Duke University Medical Center in the US.

It was halted before achieving the planned enrolment of 52,000 patients, compromising its statistical power. As a result, GUARD-AF cannot give a conclusive answer on the role of Zio XT on stroke prevention, and "further studies with longer follow-up and including participants at higher risk for stroke are needed to establish the true potential of AFib screening" in this setting, said Lopes.

AFib is the most common heart rhythm disorder, affecting more than 40 million people worldwide, and estimates suggest that one in three Europeans will develop the condition during their lifetime.

In the UK, Zio XT was recommended by health technology assessment (HTA) agency NICE in 2020 as an option for people with suspected cardiac arrhythmias who would benefit from ECG monitoring for longer than 24 hours in a pilot project that aims to gather information on NHS use.

It offers a lighter, discreet alternative to Holter monitoring, which requires patients to wear several electrodes, as well as a bulky monitor.

Recent trials have shown that one-time brief screening for AFib did not significantly increase diagnoses of the disorder, while others investigating longer-term screening found an increase in AFib diagnoses. However, none have yet established that screening lowers stroke rates.

"Our results add to the body of evidence around AFib screening and highlight the challenges in determining the impact […] on clinical outcomes," said Lopes. "Until we have clear information on who should be screened, how and for how long, and its real impact in stroke prevention, AFib screening should not be routinely recommended."

He added, however, that the study confirms that AFib is common in older patients and can be identified with cardiac monitoring in primary care – upstream of cardiology care, which many patients will not have access to."

It also showed that most (88%) of the patients with a positive identification had low-burden paroxysmal AFib, short, infrequent episodes that would be missed with a pulse check or shorter single-lead ECG monitoring.

"Identification of these short episodes could be a useful prompt for physicians to more aggressively treat heart disease risk factors and may reduce the downstream risk of heart failure, which will be evaluated in future trials," concluded Lopes.

For iRhythm, the mixed results could reduce enthusiasm for the technology, although, it still has other shots on goal including the AMALFI study in the UK, which is testing the wearable's role in detecting AFib in an NHS context. Data from that trial should start to emerge within the next 12 months or so.

Other studies are looking at the wearable in preventing heart failure, which occurs in one-third of patients with AFib, along with cardiovascular hospitalisations, and whether it can reduce the use of healthcare resources and cut costs.

https://pharmaphorum.com/news/irhythm-wearable-heart-monitor-raises-afib-diagnoses-52

Japan's Kirin clinched Fancl takeover to propel health pivot, president says

 Japan's Kirin Holdings has secured enough shares to take over supplement maker Fancl, its new president said, overcoming rival buying by an overseas fund and furthering the beermaker's transition into healthcare.

Takeshi Minakata, who rose to the top role in the company in March, said he wanted to declare victory when Kirin's tender offer was due to close on Wednesday, but financial regulations forced an extension to Sept. 11 after Hong Kong-based MY.Alpha Management lifted its stake in Fancl to around 10%.

"We are confident about it," Minakata told Reuters on Wednesday. "It's a bit of a shame that investors will have to wait another 10 days, but our stance hasn't changed, nor the money amount, and we believe the Kirin group is the best partner for Fancl."

As of Thursday, Fancl had a market value of 364.1 billion yen ($2.52 billion).

With previous roles heading Kirin's drug subsidiary and vitamin maker Blackmores Ltd, purchased in 2023 for $1.2 billion, Minakata's accession signalled a resolve to pivot from alcohol businesses that face shrinking markets in Japan and shifting consumer tastes overseas.

Kirin in June launched a 220 billion yen ($1.5 billion) tender offer for the roughly 70% of Fancl it did not already own. Kirin later extended the tender period and raised its offer amid continued share purchases by MY.Alpha.

MY.Alpha, which has managed the Asian hedge fund business of York Capital Management Global Advisors, did not reply to a request for comment on its investment strategy in Fancl.

Fancl, known for its skin cleansing oils and nutritional additives, fits into a health science portfolio that Kirin aims to grow into a new pillar of the group along with alcohol and pharma. The company aims to expand the unit's annual revenue to 500 billion yen, about five fold last year's tally.

But organic growth will not be enough to get there, likely necessitating more overseas acquisitions, Minakata said.

"We are naturally aiming for companies with a certain level of unique technology, products and brands," he said. "In that sense, North America is a big market that is still growing significantly. I think it has great potential."

Minakata joined Kirin in 1984, two years after the company leveraged its fermentation know-how to make its first foray into the pharma sector. He acknowledged it may take time for consumers, particularly those overseas, to associate the Kirin brand with drugs and health food rather than alcohol.

The timing for the push into supplements is hardly ideal given broad consumer concerns following a tainted red yeast product from Kobayashi Pharmaceutical that was linked to dozens of deaths in Japan this year.

The scandal led to the resignation of two top executives of the 105-year-old company, a plunge in its shares and calls for increased scrutiny of so-called functional foods with health benefit claims.

Minakata said Kirin has sufficient quality controls to allay the risk of venturing into supplements and other products that have shorter scientific track records.

"We have a process in place to earn the same level of trust for all our products, regardless of how long or short the development period is," he said.

In its legacy beer and beverage businesses, Kirin remains in fierce competition with Asahi Group Holdings, Suntory Holdings, and Sapporo Holdings for the same domestic market. Analysts have long said the sector is due for consolidation.

Now with Japanese retail giant Seven & i Holdings receiving a surprise takeover bid from Canada's Alimentation Couche-Tard last week, the possibility of foreign buyouts has become all the more salient. Minakata said Kirin would have to consider any serious offer it received.

"We have to keep in mind that such a possibility is not zero at all," he said. "We need to demonstrate that each of our three main businesses is finding value in its own way, and we need to do so more effectively."

https://www.yahoo.com/news/japans-kirin-clinched-fancl-takeover-010118533.html

'Biden with Harris campaign in Pennsylvania as Israel crisis intensifies'

 U.S. President Joe Biden will join Vice President Kamala Harris on the campaign trail this week for the first time since Harris replaced him at the top of the Democratic ticket, but the discovery of Israeli hostage deaths in Gaza over the weekend is likely to overshadow events.

This week marks the start of the vital post-Labor Day sprint to the Nov. 5 election, and both Harris and her Republican challenger former President Donald Trump are expected to ramp up outreach to voters, especially in battleground states such as Pennsylvania, Michigan and Nevada.

Over the weekend, Israel recovered the bodies of six hostages from a tunnel in Gaza where it said they were recently killed by Hamas, sparking sharp criticism of the Biden administration's ceasefire strategy and new pressure on Israeli Prime Minister Benjamin Netanyahu to bring the remaining hostages home.

The U.S. government, including Biden himself, has been trying to broker a ceasefire between Hamas and Israel, which has killed over 40,000 Palestinians in response to Hamas's Oct. 7 attack that killed 1,200, for months. The issue is weighing on the U.S. election, with pro-Palestinian activists threatening to ramp up protests of Harris on the campaign trail and Republicans blaming Biden and Harris for the hostage deaths.

On Monday, Biden and Harris will campaign together in Pittsburgh, Pennsylvania, one of the most important battleground states in this election cycle. Harris will also travel to Detroit, Michigan and her vice presidential pick Minnesota Governor Tim Walz will travel to Milwaukee, Wisconsin.

Before they campaign, though, Biden and Harris will meet at the White House with the U.S. hostage deal negotiating team to discuss efforts toward a deal that secures the release of the remaining hostages, the White House said.

Meanwhile, Trump will participate in a FOX town hall on Wednesday hosted by Sean Hannity, and later this week will address the Fraternal Order of Police at their fall meeting in Charlotte, North Carolina and hold a rally in Wisconsin.

A recent Reuters/Ipsos poll found that Harris was leading the race against Trump 45% to 41%.

Harris and Walz are hoping to keep up the enthusiasm her entry into the race on July 21 sparked among Democrats, who are donating record amounts of money to the campaign and volunteering by the tens of thousands. They have focused on an upbeat, positive message about America's future, cost-cutting plans aimed at the middle class and attracting Republicans turned off by Trump.

Meanwhile, Trump and his vice presidential pick JD Vance have struggled to find a clear line of attack against Harris, painting her both as an unrepentant liberal and as the inheritor of Biden's more centrist policies, while also bashing her intelligence and spreading crude internet memes.

An outside adviser to Trump previously told Reuters on condition of anonymity that several advisers had told Trump that a continued focus on insults rather than policy could doom his chances in November.

Harris' campaign appears to be outraising Trump's - last week, the Harris campaign told the Federal Election Commission that it raised $204 million in July, compared with $48 million reported to the body by Trump's main fundraising group. Both sides are bombarding battleground states with TV ads.

HOSTAGE BODIES COMPLICATE CEASEFIRE TALKS

Biden, Harris and Trump all released statements over the weekend after the six hostage bodies were found. Biden said he was "devastated and outraged," adding, "Hamas leaders will pay for these crimes. And we will keep working around the clock for a deal to secure the release of the remaining hostages."

Harris said she and her husband had spoken to the parents of Hersh Goldberg-Polin, one of the hostages whose body was found. "As they mourn this terrible loss, they are not alone. Our nation mourns with them."

Trump said the "Hostage Crisis in Israel is only taking place because Comrade Kamala Harris is weak and ineffective, and has no idea what she's doing."

Leat Corinne Unger, a family member of 21-year-old Israeli hostage Omer Shem Tov, who was not one of the hostages found over the weekend, told Reuters that "everyone has failed."

"Everyone has blood on their hands," she said. "The international community failed, the administration, on both sides, bipartisan, they failed."

"It's time for the suffering of innocents to end on all sides of the spectrum and the international community must hold Hamas accountable," she added. "They have said a lot of things, but they haven't done anything to force their hand."

Biden and Harris are likely to face more questions about what the administration is doing to secure a hostage deal, said Jeremi Suri, history and public affairs professor at the University of Texas at Austin.

"The best scenario for Biden and Harris would be a ceasefire this week," Suri said. "Israeli public is pushing and Hamas seems open, but it is very hard to predict."

https://www.yahoo.com/news/biden-harris-campaign-pennsylvania-israel-100416458.html